2233404
Project Grant
Overview
Grant Description
SBIR Phase I: Targeting the root cause of Ewing's sarcoma - The broader impact of this Small Business Innovation Research (SBIR) Phase I project is to treat pediatric patients affected with Ewing's sarcoma by targeting the root cause of the disease. Using a novel approach, new therapeutics will be developed to specifically inhibit the protein that causes Ewing's sarcoma and thereby extend the lifespan of patients.
The approach will enable understanding of the molecular underpinnings of this devastating disease. Importantly, findings from this study may be able to treat diseases driven by similar proteins, providing new medication for patients with few available treatment options.
The successful outcome of the project would lead to the commercialization of the first-in-class inhibitor to target the oncogenic fusion protein, EWS-FLI1, to treat Ewing's sarcoma. In addition, the technology could provide valuable data about drugging oncogenic proteins in other diseases such as prostate cancer and breast cancer.
This project will aid in characterizing potential therapies for Ewing's sarcoma. The goals include: (1) determining the toxicity profile of novel inhibitors across a panel of human cells, (2) measuring the drug specificity to the target protein, and (3) determining the efficacy of the lead molecule in mice.
The data from this study will add to the understanding of drugging fusion proteins which are validated drivers of many diseases such as prostate cancer, breast cancer, and Ewing's sarcoma.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria. Subawards are planned for this award.
The approach will enable understanding of the molecular underpinnings of this devastating disease. Importantly, findings from this study may be able to treat diseases driven by similar proteins, providing new medication for patients with few available treatment options.
The successful outcome of the project would lead to the commercialization of the first-in-class inhibitor to target the oncogenic fusion protein, EWS-FLI1, to treat Ewing's sarcoma. In addition, the technology could provide valuable data about drugging oncogenic proteins in other diseases such as prostate cancer and breast cancer.
This project will aid in characterizing potential therapies for Ewing's sarcoma. The goals include: (1) determining the toxicity profile of novel inhibitors across a panel of human cells, (2) measuring the drug specificity to the target protein, and (3) determining the efficacy of the lead molecule in mice.
The data from this study will add to the understanding of drugging fusion proteins which are validated drivers of many diseases such as prostate cancer, breast cancer, and Ewing's sarcoma.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria. Subawards are planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF22551
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
San Carlos,
California
94070-3310
United States
Geographic Scope
Single Zip Code
Related Opportunity
22-551
Altay Therapeutics was awarded
Project Grant 2233404
worth $275,000
from National Science Foundation in September 2023 with work to be completed primarily in San Carlos California United States.
The grant
has a duration of 1 year and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I:Targeting the Root Cause of Ewing’s Sarcoma
Abstract
The broader impact of this Small Business Innovation Research (SBIR) Phase I project is to treat pediatric patients affected with Ewing’s Sarcoma by targeting the root cause of the disease. Using a novel approach, new therapeutics will be developed to specifically inhibit the protein that causes Ewing’s Sarcoma and thereby extend the lifespan of patient. The approach will enable understanding of the molecular underpinnings of this devastating disease. Importantly, findings from this study may be able to treat diseases driven by similar proteins, providing new medication for patients with few available treatment options.The successful outcome of the project would lead to the commercialization of the first-in-class_x000D_ inhibitor to target the oncogenic fusion protein, EWS-FLI1, to treat Ewing’s Sarcoma. In addition, the technology could provide valuable data about drugging oncogenic proteins in other disesases such as prostate cancer and breast cancer._x000D_ _x000D_ This project will aid in characterizing potential therapies for Ewing’s Sarcoma. The goals include: (1) determining the toxicity profile of novel inhibitors across a panel of human cells, (2) measuring the drug specificity to the target protein, and (3) determining the efficacy of the lead molecule in mice. The data from this study will add to the understanding of drugging fusion proteins which are validated drivers of many diseases such as prostate cancer, breast cancer, and Ewing’s Sarcoma._x000D_ _x000D_ This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
PT
Solicitation Number
NSF 22-551
Status
(Complete)
Last Modified 9/22/23
Period of Performance
9/15/23
Start Date
8/31/24
End Date
Funding Split
$275.0K
Federal Obligation
$0.0
Non-Federal Obligation
$275.0K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2233404
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
DXGQLLP9NQ59
Awardee CAGE
8CFV4
Performance District
CA-15
Senators
Dianne Feinstein
Alejandro Padilla
Alejandro Padilla
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Research and Related Activities, National Science Foundation (049-0100) | General science and basic research | Grants, subsidies, and contributions (41.0) | $275,000 | 100% |
Modified: 9/22/23